Virtu KCG Holdings’s Grace Therapeutics GRCE Stock Holding History

Virtu KCG Holdings’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$42K	Buy	+661	New	+$41.1K	﹤0.01%	2627
2017 Q1	–	Sell	-469	Closed	-$28K	–	3832
2016 Q4	$28K	Sell	469 -139	-23%	-$9.33K	﹤0.01%	3193
2016 Q3	$52K	Buy	+608	New	+$45K	﹤0.01%	2774
2015 Q4	–	Sell	-23	Closed	-$3K	–	4013
2015 Q3	$3K	Buy	+23	New	+$3.86K	﹤0.01%	3265
2015 Q1	–	Sell	-341	Closed	-$82K	–	3984
2014 Q4	$82K	Buy	341 +188	+123%	+$46.3K	﹤0.01%	3297
2014 Q3	$54K	Buy	153 +95	+164%	+$44.7K	﹤0.01%	3329
2014 Q2	$29K	Sell	58 -34	-37%	-$16.2K	﹤0.01%	3492
2014 Q1	$50K	Buy	+92	New	+$56K	﹤0.01%	3334
2013 Q4	–	Sell	-46	Closed	-$53K	–	4334
2013 Q3	$53K	Buy	+46	New	+$68.4K	﹤0.01%	3498

Other funds holding GRCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

IIM

Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Virtu KCG Holdings's GRCE Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Grace Therapeutics (GRCE) in Q2 2017: 661 shares worth $42K. The stake represents ﹤0.01% of the portfolio and ranks #2627 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in GRCE as recently as Q4 2016.

Virtu KCG Holdings first reported a position in GRCE in Q3 2013 and has held it in 9 quarters since. The position peaked at $82K in Q4 2014. 9 funds tracked by Wall St. Rank hold GRCE as of Q2 2017.

Virtu KCG Holdings held 661 shares of Grace Therapeutics worth $42K as of Q2 2017.
Grace Therapeutics was a new Virtu KCG Holdings position in Q2 2017.
Grace Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2627 holding.
Virtu KCG Holdings first reported a position in Grace Therapeutics in Q3 2013 and has held it in 9 quarters since.
Virtu KCG Holdings's Grace Therapeutics position peaked at $82K in Q4 2014.
9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.